Weight Loss Linked to Better Outcomes for Arthritis Patients Using GLP-1 RAs
A study reveals that patients with rheumatoid and psoriatic arthritis experience improved health outcomes with weight loss after starting GLP-1 receptor agonists.
ORLANDO, Nov 9: Patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) who lose weight after starting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) report significant health improvements, according to findings presented at ACR Convergence 2026.
The research team conducted a retrospective cohort study using data from the ACR Rheumatology Informatics System for Effectiveness (RISE) registry. It included adult patients who had previously been prescribed at least one disease-modifying antirheumatic drug (DMARD) before beginning treatment with semaglutide or tirzepatide and tracked results from January 2018 to September 2024.
Out of 16,848 patients who started GLP-1 RA therapy, 67.3% were diagnosed with RA, and 80.2% were women. The average age of participants was 57.9 years. The researchers focused on a subgroup of 1,880 patients who completed checkups before and one year after starting the medication. Participants experienced an average weight loss of 15.6 pounds over the year.
Following this weight loss, the patients showed decreases in their Routine Assessment of Patient Index Data 3 (RAPID3) scores, which evaluate joint pain, physical function, and overall well-being, by an average of 1.3 points. The strongest improvements were found in pain and patient global assessment domains.
Multivariate linear regression analyses indicated that for every 5% reduction in body weight, RAPID3 scores improved by 0.30 points. Participants who achieved a 5% weight loss had a 14% higher likelihood of reaching a minimal clinically important difference in RAPID3 scores.
“Greater weight loss was associated with clinically meaningful improvements in RAPID3 scores,” the authors concluded.
Some researchers disclosed ties to biotechnology, pharmaceutical, and medical device companies, which may influence their findings.
Sources
My name is Kuldeep Singh Chundawat. I am an experienced content writer with several years of expertise in the field. Currently, I contribute to Daily Kiran, creating engaging and informative content across a variety of categories including technology, health, travel, education, and automobiles. My goal is to deliver accurate, insightful, and captivating information through my words to help readers stay informed and empowered.